Executive Summary

The Regenerative Medicine Advanced Therapy pathway has matured from a designation intended to improve development coordination into a recurring feature of successful cell, gene, and tissue-based product programs. The approval record shows that RMAT does not prescribe one evidentiary template. Instead, successful programs have matched the control strategy, endpoint, and approval pathway to the disease setting, expected treatment effect, and practical limits of conventional trials.

The most persuasive programs have generally used one of several recognizable architectures: randomized within-patient comparisons for localized products, single-arm trials supported by natural history for ultra-rare diseases, response-based accelerated approval in refractory oncology, and within-patient historical comparisons for durable replacement therapies. More recent approvals also show that FDA can divide a product's indications between traditional and accelerated approval when evidentiary maturity differs by subgroup.

For sponsors, the central strategic lesson is that RMAT is most valuable when designation is followed by disciplined use of FDA interactions. The development program still requires a credible estimand, a control strategy that can withstand bias, an endpoint linked to clinical benefit, an executable confirmatory plan when accelerated approval is used, and a manufacturing package capable of supporting the commercial product.

What RMAT Changes, and What It Does Not

The Regenerative Medicine Advanced Therapy (RMAT) designation was created by the 21st Century Cures Act, enacted on December 13, 2016. A product must be a regenerative medicine therapy intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, and preliminary clinical evidence must indicate the potential to address an unmet medical need. A request may be submitted with or after an Investigational New Drug (IND) application, and the U.S. Food and Drug Administration (FDA) states that it will respond within 60 calendar days. 1

RMAT designation provides the intensive development interaction associated with breakthrough therapy designation and permits discussion of potential accelerated approval strategies for regenerative medicine therapies. It does not itself establish substantial evidence of effectiveness, guarantee priority review, authorize rolling submission in every case, or predetermine whether approval will be traditional or accelerated. Those decisions remain tied to the product-specific evidence and the applicable statutory standard. 12

The FDA's Center for Biologics Evaluation and Research (CBER) reported 31 RMAT requests and 11 grants in fiscal year 2017. By fiscal year 2025, annual volume had increased to 91 requests and 50 grants. Across fiscal years 2017 through 2025, the published CBER table totals 388 requests and 193 grants, showing both wider use of the pathway and substantial selectivity at the designation stage. 3

The Approval Record Through July 2026

FDA's public RMAT approvals include 14 original approvals through September 30, 2025, beginning with Breyanzi in February 2021. Product-specific FDA materials identify five additional RMAT-designated approvals from December 2025 through June 2026: Avance, Waskyra, Kresladi, Otarmeni, and Tregzi. This produces a current identified total of 19 original approvals through July 10, 2026. 456789

FDA RMAT Approvals Timeline

Click to enlarge

The sequence is strategically important because it demonstrates that RMAT has supported a broad range of modalities and evidentiary settings, including autologous and allogeneic cell therapies, ex vivo and in vivo gene therapies, tissue-engineered products, and regenerative scaffolds. The record also includes both traditional and accelerated approvals, indicating that RMAT is a platform for regulatory engagement rather than a single approval route. 410578

Study-Design Patterns Behind Approval

Localized products can create unusually efficient randomized evidence by using the patient as the control. StrataGraft's Phase 3 study was open-label, intra-subject, autograft-controlled, and randomized, with comparable burn wounds assigned to StrataGraft or autograft. Vyjuvek was evaluated in a multicenter, randomized, double-blind, placebo-controlled study in which matched wounds within the same patient received active treatment or placebo. For dystrophic epidermolysis bullosa (DEB), the paired-wound approach reduced between-patient heterogeneity while preserving prospective randomization and blinding. These designs are especially relevant when multiple comparable lesions can be measured independently and treatment has a local rather than systemic effect. 1112

Ultra-rare diseases with predictable natural history can support externally controlled development when randomization is infeasible or ethically difficult. For Rethymic, FDA identifies a natural history study of 49 patients as the external control for pooled data from 10 prospective, single-center, open-label studies. The regulatory strength came from the seriousness of congenital athymia, the untreated mortality context, and an effect that could be interpreted against the expected disease course. This model depends on endpoint comparability, aligned eligibility, credible follow-up, and a treatment effect large enough to resist residual confounding. 13

Refractory oncology programs have used single-arm evidence when objective response and durability can be interpreted in a population with limited options. Amtagvi received accelerated approval for unresectable or metastatic melanoma based on response rate and duration of response from a multicenter trial of autologous tumor-infiltrating lymphocytes. This architecture can reach approval without a randomized pivotal comparison, but the evidentiary burden shifts toward independent response assessment, durability, safety characterization, and completion of confirmatory evidence. 10

Durable hematologic and genetic therapies can use a patient-as-own-control framework when a reliable pretreatment history exists. Casgevy's sickle cell disease program used a single-arm design and evaluated whether treated participants remained free of severe vaso-occlusive crises for a sustained period after therapy. The design linked an individualized manufacturing intervention to a clinically direct outcome and avoided reliance on a laboratory surrogate as the sole basis for the initial sickle cell disease approval. 14

Tregzi demonstrates that RMAT can coexist with a conventional randomized controlled design when disease prevalence and clinical practice permit one. FDA evaluated the product in Precision-T, a multicenter, open-label, randomized trial comparing Tregzi followed by single-agent graft-versus-host disease prophylaxis with an unmanipulated allograft followed by standard two-drug prophylaxis. The primary endpoint was chronic graft-versus-host disease-free survival, adjudicated by a blinded independent committee. This design directly tested the integrated transplant strategy rather than relying on response rate, a biomarker, or historical control. 9

The Avance approval illustrates indication segmentation rather than a single all-or-nothing decision. FDA granted traditional approval for sensory nerve discontinuities with gaps of 25 millimeters or less and accelerated approval for longer sensory gaps and certain motor or mixed nerve discontinuities. The same product therefore entered the market under different evidentiary statuses, with confirmatory obligations attached to the accelerated indications. This approach may be relevant when a common platform has mature evidence in one anatomically or clinically defined subgroup but residual uncertainty in another. 5

Accelerated Approval Is Selective, Not Intrinsic

Accelerated approval is available within RMAT development, but it is not inherent to the designation. The approval record includes traditionally approved products such as Vyjuvek and Casgevy, as well as accelerated approvals such as Amtagvi, Kresladi, and Otarmeni. Avance combines both routes within one label. The relevant question is not whether a product has RMAT designation, but whether the proposed endpoint and evidence satisfy the requirements for the selected approval pathway. 121410785

Kresladi shows the logic of a biologically anchored accelerated approval in an ultra-rare immune disorder. FDA approved the product for severe leukocyte adhesion deficiency type I based on an increase in neutrophil CD18 and CD11a expression, with continued approval contingent on verification and description of clinical benefit. The strategy depends on a mechanistically coherent biomarker, an analytically reliable assay, a persuasive relationship between expression and disease biology, and a confirmatory program capable of establishing clinical benefit. 7

Otarmeni shows a different accelerated model. FDA granted accelerated approval for otoferlin-related hearing loss based on hearing improvement, while requiring additional evidence on durability and clinically meaningful functional outcomes, including speech development and quality of life. The program demonstrates that a direct physiological improvement may still leave uncertainty about persistence and downstream patient benefit, particularly in young children whose language development unfolds over time. 8

Sponsors considering accelerated approval should therefore treat the confirmatory study as part of the initial development architecture, not as a postapproval administrative step. Population, endpoint, assay, manufacturing process, enrollment feasibility, and timing must be designed early enough that the confirmatory program can begin promptly and remain interpretable if standards of care change. FDA's 2025 draft guidance specifically addresses accelerated approval and clinical development considerations for regenerative medicine therapies, although the document remains draft guidance and is not binding. 21078

Regulatory Interaction and Manufacturing Strategy

The practical value of RMAT lies in structured access to multidisciplinary FDA interaction. FDA describes an Initial Comprehensive Meeting after designation to discuss the development program, including planned clinical trials and manufacturing strategy, followed by milestone meetings as development advances. For a Biologics License Application (BLA), this creates an opportunity to align the clinical, statistical, pharmacology, device, and Chemistry, Manufacturing, and Controls (CMC) workstreams before late-stage assumptions become difficult to reverse. 15

The highest-value meetings are decision-oriented. Sponsors should arrive with a defined target population, proposed control strategy, endpoint hierarchy, missing-data approach, duration of follow-up, safety database plan, and explicit questions about the evidentiary route. A request for general feedback is less useful than presenting competing designs and asking which residual uncertainties each design would leave at approval. RMAT interaction can compress iteration, but it cannot compensate for an undefined estimand or an endpoint that is disconnected from patient benefit. 152

Manufacturing strategy must progress in parallel with clinical strategy because the product used to generate pivotal evidence must remain meaningfully comparable to the proposed commercial product. FDA has described lifecycle approaches to process validation, flexibility in the number of process performance qualification lots for small populations, and risk-based handling of certain manufacturing changes. These flexibilities do not remove the need for validated analytical methods, release specifications, potency strategy, contamination control, stability, and a comparability argument that protects the relevance of the clinical data. 16

For autologous products, operational design is also part of the evidence strategy. Chain of identity, manufacturing turnaround, bridging after process changes, treatment-center execution, and management of patients who are enrolled but do not receive product can affect the estimand and the interpretability of real-world effectiveness. For allogeneic and off-the-shelf products, batch consistency, donor strategy, persistence, immunogenicity, and repeat-dosing assumptions can become central. The regulatory plan should define these risks before pivotal enrollment rather than treating them solely as commercial launch issues. 216

Publicly Disclosed Programs Still in Development

FDA's public designation statistics are aggregate rather than a complete named roster of investigational products. The development-stage landscape must therefore be assembled from sponsor disclosures and is necessarily incomplete. Publicly announced designations show continued expansion beyond approved oncology and rare-disease programs into autoimmune disease, inherited retinal disease, neurodegeneration, genetic epilepsy, allogeneic cell therapy, and precision transplantation. 3171819202122232425

Several advanced programs illustrate how RMAT interaction can shape the registrational package. Kyverna reported FDA alignment for a rolling BLA for miv-cel in stiff person syndrome based on a single-arm pivotal Phase 2 trial, with natural history data providing context. uniQure reported that FDA would accept the three-year AMT-130 analysis against a prespecified, propensity score-matched external control as the primary basis for a planned accelerated approval BLA in Huntington's disease. Encoded Therapeutics reported alignment on a 30-patient, randomized, double-blind, sham delayed-treatment pivotal study for ETX101 in young children with Dravet syndrome. 171819

Deramiocel provides an important counterexample to any assumption that RMAT designation predicts a smooth review. Capricor reported that FDA issued a Complete Response Letter in July 2025, then resumed review after the sponsor submitted Phase 3 HOPE-3 evidence and supporting documentation. As of July 10, 2026, the sponsor reported an August 22, 2026 action date for the resubmitted BLA. The case shows that enhanced interaction does not displace the requirement for an adequate effectiveness package. 20

Earlier-stage disclosures show the pathway being used to address different development risks. FT819 and CB-011 place allogeneic cell manufacturing, persistence, and durability at the center of FDA interaction. Laru-zova and OPGx-LCA5 require alignment on functional vision endpoints and long-term ocular follow-up. Orca-Q must integrate graft composition, conditioning, donor matching, and transplant outcomes. Designation in these settings confirms that the statutory threshold was met, but it does not resolve pivotal design, manufacturing readiness, or approvability. 2122232425

Implications for Development Strategy

The designation request should be timed around interpretable preliminary clinical evidence, not merely the availability of a first safety dataset. The strongest request links the observed effect to a defined unmet need, explains why the endpoint is clinically meaningful, characterizes durability to the extent available, and shows that the treated population is relevant to the intended development path. A statistically unstable or biologically ambiguous signal may satisfy neither the statutory threshold nor the practical objective of obtaining useful program-level alignment. 12

Control selection should follow the biology and delivery model. Local products should evaluate paired-site or within-patient randomization when feasible. Ultra-rare systemic diseases should invest early in natural history datasets with aligned definitions and follow-up. Where a credible active comparator and adequate enrollment are feasible, parallel-group randomization should remain the default. Refractory oncology programs should pre-specify independent response assessment and duration analyses. Chronic event-driven diseases should prospectively establish the quality of pretreatment history before relying on within-patient comparison. 121391014

Endpoint strategy should distinguish immediate biological activity from durable clinical benefit. Kresladi and Otarmeni show that an endpoint can support accelerated approval while leaving separate questions about long-term function, development, or survival. The confirmatory trial must answer those residual questions rather than simply reproduce the same short-term signal in another cohort. 78

Manufacturing changes should be planned as a sequence of controlled transitions. Sponsors should define the intended commercial process early, reserve representative material, maintain analytical continuity, and identify which changes could alter potency, biodistribution, persistence, or clinical performance. FDA's stated flexibilities are most useful when supported by a coherent risk assessment and a strong comparability package, not when invoked after major process drift has already occurred. 1615

Finally, RMAT strategy should be indication-specific. Avance demonstrates that different subgroups can receive different approval routes, while the wider approval record shows that the same designation can lead to traditional approval, accelerated approval, or a prolonged development program. Sponsors should define the narrowest population in which benefit can be demonstrated convincingly, then sequence expansion rather than forcing heterogeneous populations into a single pivotal hypothesis. 54

Conclusion

RMAT has become a durable part of FDA's framework for regenerative medicine, but the approvals do not support a shortcut narrative. The designation has been most consequential when sponsors used early clinical evidence to secure alignment on a design that fit the disease and product, then carried that logic through endpoints, manufacturing, confirmatory evidence, and labeling.

The critical regulatory choice is therefore not whether to pursue RMAT in the abstract. It is whether the program has enough human evidence and operational maturity to use enhanced interaction productively. Programs that can explain their control strategy, define the remaining uncertainty, and show how each development step resolves that uncertainty are positioned to extract the greatest value from the pathway.